AAV Therapy

Edinburgh, UK | May 28, 2026 Clinical-stage oncology company Trogenix announced the first patient has been dosed in the...

PHILADELPHIA & BOSTON, April 28, 2026 Latus Bio, Inc. has announced new preclinical and computational data supporting its investigational...

Waltham, Massachusetts, USA, April 6, 2026 Health Canada Approval Marks Key Clinical Milestone In a significant development for cardiovascular...

RESEARCH TRIANGLE PARK, N.C., USA, March 31, 2026 AskBio, a wholly owned and independently operated subsidiary of Bayer AG,...

EGENXBIO Inc. (Nasdaq: RGNX) announced positive 12-month pivotal data from its Phase I/II/III CAMPSIITE® trial of RGX-121 (clemidsogene lanparvovec),...